After 50 years, St. Michael’s Hospital remains at the forefront of kidney care
Our history of innovations has been remarkable. But we never rest on our laurels. St. Michael’s clinicians and scientists are always at the forefront of new discovery.
St. Michael’s clinicians and scientists are always at the forefront of new discovery.
- St. Michael’s helped solve the problem of incompatible donors and recipients. This is how it works: family members and friends who wish to donate a kidney but aren’t compatible with their loved one are matched with another donor-recipient pair with the same problem. A “swap” is made so that each recipient gets a kidney. Before this program, 20 per cent of living donors were excluded because they didn’t match the intended recipient.
- We are the only transplant centre in North America to offer blood-type-incompatible transplants with Glycosorb®, a technology that enables patients to accept a kidney from a donor with a different blood type.
- St. Michael’s was the first transplant program in Ontario to utilize minimally invasive surgery on living kidney donors. Smaller incisions mean less trauma, less scarring, less pain and reduced recovery time.
- We have North America’s most ethnically diverse transplant population. We were the first in the world to discover that South Asians experience a higher risk of cardiac events following a transplant, resulting in a change of protocols for this population. And we have a robust international program that has brought living donors from 81 countries. In one case, it took us a mere 21 days to bring a donor from overseas and perform the transplant on our patient here in Canada.
- We conducted the most extensive clinical research in Canada on a new drug formulation: Tacrolimus is an anti-rejection medication essential for transplant patients. As a result of our work, once-daily tacrolimus has been helping kidney transplant patients since 2005.
- We conducted the world’s largest clinical trial on dialysis start times: STARRT-AKI set out to determine the optimal time for those with acute kidney injury, a patient group with a high mortality rate, to begin dialysis. St. Michael’s nephrologist Dr. Ron Wald co-led the international trial, which included almost 3,000 patients in 14 different countries. The trial showed there was no significant difference in either survival or post-treatment dialysis dependence between an accelerated or standard treatment strategy; this result influences care protocols for these critically ill patients.
The Jamie Merbaum story
“I now celebrate a second birthday because St. Michael’s Hospital saved my life.”Read article
St. Michael’s launches COVID-19 podcast series
Facts from the Frontlines: COVID-19 weekly podcast series.Read article
Valerie Armstrong thought her days were numbered
Cancer patient was given a death sentence until she came to St. Michael’s Hospital.Read article
Women in medical leadership: Where to now?
Dr. Carolyn Snider, chief of Emergency Medicine, on why women still lag behind men in medical leadership and what can be done about it.Read article
Why I became a St. Michael’s donor
Joan Shellnutt, mother of patient David Shellnutt, tells the story of how St. Michael’s saved her son’s life and why she wants to give back.Read article
St. Michael’s kidney transplant patient Dave Ayres makes NHL history
“There are so many brilliant doctors at St. Michael’s who keep you going. I didn’t want the kidney transplant to dictate my life. They told me to go ahead and live. That’s exactly what I’m doing.”Read article